Ads
related to: mantle cell lymphoma treatment- MCL Treatment Option
Learn About Mantle Cell Lymphoma
And Explore A Treatment Option
- Safety & Side Effects
Read Important Safety Information
Along With Possible Side Effects
- Download Brochure
Get Info On A R/R MCL Treatment
Option With A Downloadable PDF
- Patient Support
See How Cell Therapy May Treat MCL
With Info For Patients & Caregivers
- MCL Treatment Option
Search results
Results from the WOW.Com Content Network
Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma, comprising about 6% of cases. [1] [2] It is named for the mantle zone of the lymph nodes where it develops.[3] [4] The term 'mantle cell lymphoma' was first adopted by Raffeld and Jaffe in 1991.
Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy medication for the treatment of mantle cell lymphoma (MCL) [10] [11] [7] and acute lymphoblastic leukemia (ALL). [12] The most common side effects include serious infections, low blood cell counts and a weakened immune system. [10]
Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL).
Pirtobrutinib, sold under the brand name Jaypirca, is an anticancer medication that is used to treat mantle cell lymphoma. [1] [2] [4] It inhibits B cell lymphocyte proliferation and survival by binding and inhibiting Bruton's tyrosine kinase (BTK). [5] It is taken by mouth. [1]
Recently, the FDA approved AstraZeneca’s Calquence in combination with bendamustine and rituximab for adult patients with previously untreated mantle cell lymphoma who are ineligible for ...
It was approved by the US Food and Drug Administration (FDA) in November 2013, for the treatment of mantle cell lymphoma. [10] In February 2014, the FDA expanded the approved use of ibrutinib to chronic lymphocytic leukemia (CLL). [25] [26] It was approved for Waldenström's macroglobulinemia in 2015. [11] [27]
Four chimeric antigen receptor T cell therapies are FDA-approved for non-Hodgkin lymphoma, including lisocabtagene maraleucel (for relapsed or refractory large B-cell lymphoma with two failed systemic treatments), axicabtagene ciloleucel, tisagenlecleucel (for large B-cell lymphoma), and brexucabtagene autoleucel (for mantle cell lymphoma ...
R-miniCHOP is indicated in elderly patients (>80 years) with diffuse large B-cell lymphoma due to less toxicity from the reduced dose in comparison to R-CHOP. R-Maxi-CHOP is used in mantle cell lymphoma and is given in 21-day intervals, alternating with R-HDAC (rituximab + high-dose cytarabine). [3]
Ads
related to: mantle cell lymphoma treatment